中科生物盈喜：预期中期净利900万元

Group 1 - The company expects to record a net profit attributable to shareholders of approximately RMB 9 million for the six months ending June 30, 2025, compared to a net loss of RMB 1.7 million for the same period ending June 30, 2024 [1] - The turnaround to profitability is primarily due to the recognition of foreign exchange gains of approximately RMB 16 million for the six months ending June 30, 2025 [1]